Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of ENX-104
NL-OMON58944Phase 1Completed
- Sponsor
- Engrail Therapeutics
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ENX-104 in major depressive disorder (MDD), sponsored by Engrail Therapeutics. Primary endpoint: Primary endpoint(s). Started Jul 2024; status: completed.
02
Drugs
ENX-104
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON58944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58944.